Vie. Dic 4th, 2020

In the past few decades, medical institutions had begun to use cannabis a form of treatment, as a result of its multifarious therapeutic effects. Researchers have conducted years of studies in order to understand the plant and its effects further. Positive results have thus allowed the integration of cannabis into medical facilities, but it also helped propel the global legalization efforts. The active components in cannabis, THC and CBD, are linked to possessing beneficial effects on the body, which make them popular options for treatment. Currently, cannabis is predominately being used to treat mild to severe medical conditions such as chronic pain, cancer, epilepsy, and seizures. And according to data compiled by Acute Market Reports, the global medical marijuana market was valued at USD 13.9 Billion in 2017 and is expected to reach USD 57.58 Billion by 2026. Additionally, the market is projected to expand at a healthy CAGR of 17.1% throughout the forecast period from 2018 to 2026. Dispensaries are expected to flourish during the period because they offer a wide range of products, including remedies to treat pain even though medical institutions may look to use certain biotechnology or pharmaceutical manufacturers’ products to treat more severe conditions. With the rates of medical cases like cancer continually rising year over year, it is projected that the demand for medical cannabis will increase throughout the period as well. Pressure BioSciences, Inc. (OTC: PBIO), Aphria Inc. (NYSE: APHA) (TSX: APHA), Neptune Wellness Solutions Inc. (NASDAQ: NEPT) (TSX: NEPT), Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE), AXIM Biotechnologies, Inc. (OTC: AXIM).                      

North America is the global leader in the medical cannabis industry, primarily due to its rising prevalence of cancer and proactive policies. Canada has fully legalized cannabis entirely, while the U.S. boasts just over 30 states that have adopted cannabis for medical use. The U.S. is the largest cannabis market globally despite not having legalized cannabis entirely on a federal scale. However, ongoing legalization efforts have made regulations regarding the plant much more lenient. Regulations have allowed manufacturers to produce cannabis not only in forms of flower, but also in different variations like capsules, tinctures, creams, and even oils. On the other hand, federal regulations regarding THC are still heavily enforced around theU.S. CBD, though, is completely legalized because of its non-psychoactive effects. «CBD can supplement a depleted ECS system by working to ease the unfriendly symptoms in the body with the goal to help the body achieve homeostasis, or balance. Just like our body produces calcium, and some people take calcium supplements, we can use CBD in the same way,» said Tisha Trautsch,  RN, BSN, who recently led a course on about the history, products and potential benefits of CBD, «This isn’t a cure, it’s a supplement. But it is very up-and-coming. It’s coming hard and it’s coming fast.» 

Pressure BioSciences, Inc. (OTCQB: PBIO) just earlier this morning announced breaking news that, «a short video demonstrating the Company’s proprietary Ultra Shear Technology (UST™) platform and its ability to create extremely small, nanometer-scale oil droplets that effectively dissolve in water (nanoemulsions) to provide optimized bioavailability for absorption.

Dr. Bradford A. Young, Chief Commercial Officer of Pressure BioSciences, explained: «We have all observed how oil and water do not normally mix or dissolve in each other, and routinely separate after mixing.  Even with modern, advanced mixing technologies, oils remain in relatively large drops in water, which are poorly absorbed by the body. PBI’s proprietary UST platform employs ultra-high pressure and extreme shearing forces to create very small, nano-scale emulsions (nanoemulsions) of oil droplets in water with vastly improved absorption and stability characteristics.»

Bioavailability describes the percentage of and rate at which a substance is absorbed into the bloodstream. Oil-water emulsions of nutraceuticals and supplements present a serious challenge for many oral and transdermal therapies, due to most of the beneficial molecules remaining hidden inside of the oil drops. For CBD products commonly consumed orally – including CBD oils in edibles and beverages – absorption is typically below 10% (RawlsMD.com, 8/22/18, The Science Behind CBD Oil: Everything You Need to Know). PBI believes that processing with the UST platform will deliver greatly improved absorption results (90% or higher) for CBD and other oil-based supplements.

Dr. Young continued: «For many oil-based products, the ability to create nanoemulsions can improve a product’s absorption, medicinal benefits, visual appearance, and sensory presentation. The potential for the UST platform to impact the CBD industry is promising, with the total cannabinoid market expected to hit $22 billion by 2022 (Brightfield Group, 2018), with CBD oil-based supplements being the cornerstone of this market. More importantly, while CBD is an attractive opportunity for our proprietary UST platform, we believe that the nutraceuticals, topicals and cosmetics, and food and beverage markets as mentioned could be 10-50 times larger.  We will be addressing these additional market opportunities in parallel with our efforts in CBD.»

The short video released today is the first in a series of product-targeted video presentations designed to offer investors, future clients, and other interested groups additional information on PBI’s UST platform and the numerous applications and opportunities for this transformational, proprietary technology. 

e-mail icon
Facebook icon
Twitter icon
LinkedIn icon
Reddit icon
Rate this article: 

Regional Marijuana News: 

Por admin